Abstract
Background
Classic phenylketonuria (PKU) is due to an inborn error of metabolism resulting in an inability to metabolize the amino acid phenylalanine. To avoid mental retardation, affected individuals observe a phenylalanine-restricted diet. When dietary control is poor, deficits in prefrontally mediated cognitive functions have been observed. It has been suggested that these deficits are due to disruptions in the mesocortical dopamine system that projects to the prefrontal cortex.
Methods
In this study, dopamine system reactivity was examined in individuals with PKU, relative to age-matched controls, using the non-specific DA antagonist haloperidol, in a repeated measures placebo-controlled design. Outcome variables included neuroendocrine, physiological, and cognitive measures.
Results
Regardless of drug condition, PKU participants differed from control participants in their blood phenylalanine and tyrosine levels, and in their times to complete measures of attention and working memory. Also, relative to placebo, haloperidol influenced several variables irrespective of group status, including serum prolactin secretion, times to complete attention and working memory tasks, and accuracy of working memory performance. An interaction between group and drug condition was observed for the digit span task, where PKU participants exhibited greater relative impairments on haloperidol. When composite indices of impairment were derived, PKU participants demonstrated selective disruption in executive function on haloperidol relative to control subjects.
Conclusions
Findings are consistent with the presence of frontostriatal dysfunction in PKU but are less consistent with the notion that PFC dopamine function is specifically affected.
Similar content being viewed by others
References
Banich MT, Passarotti AM, White DA, Mortz MJ, Steiner RD (2000) Interhemispheric interaction during childhood: II. Children with early-treated phenylketonuria. Dev Neuropsychol 18:53–71
Ben-Jonathan N (1985) Dopamine: a prolactin inhibiting hormone. Endocrin Rev 6:564–589
Bond AJ, Lader MJ (1974) The use of analogue scales in rating subjective feelings. Br J Med Psychol 47:211–218
Braver TS, Cohen JD (1999) Dopamine, cognitive control and schizophrenia: the gating model. Prog Brain Res 121:327–349
Carlson HE, Hyman DB, Bauman C, Koch R (1992) Prolactin responses to phenylalanine and tyrosine in phenylketonuria. Metab Clin Exp 41:518–521
Cohen J (1988) Statistical power analysis for the behavioral sciences, 2nd edn. Erlbaum, Hillsdale, N.J.
Collins P, Roberts AC, Dias R, Everitt BJ, Robbins TW (1998) Perseveration and strategy in a novel spatial self-ordered sequencing task for nonhuman primates: effects of excitotoxic lesions and dopamine depletions of the prefrontal cortex. J Cognit Neurosci 10:332–354
DeFilippis NA, McCampbell E, Rogers P (1979) Development of a booklet form of the category test: normative and validity data. J Clin Neuropsychol I:339–342
Diamond A (2001) Different functions of dorsolateral and ventrolateral prefrontal cortex. Paper presented at the 2001 Biennial Meeting of the Society for Research in Child Development, Minneapolis, Minn.
Diamond A, Prevor MB, Callender G, Druin D (1997) Prefrontal cortex cognitive deficits in children treated early and continuously for PKU. Monogr Soc Res Child Dev 62:1–208
Faust D, Libon D, Pueschel S (1986) Neuropsychological functioning in treated phenylketonuria. Int J Psychiatr Med 16:169–177
First MB, Spitzer RL, Gibbon M, Williams JBW (1997) Structured clinical interview for DSM-IV axis I disorders—patient edition (SCID-I/P, Version 2.0, 4/97 revision). New York State Psychiatric Institute, Biometrics Research Department, New York
Fray PJ, Robbins TW, Sahakian BJ (1996) Neuropsychiatric applications of CANTAB. Int J Geriatr Psychiatr 11:329–336
Goodwill KE, Sabatier C, Marks C, Raag R, Fitzpatrick PF, Stevens RC (1997) Crystal structure of tyrosine hydroxylase at 2.3A and its implications for inherited neurodegenerative diseases. Nature Struct Biol 4:578–585
Gourovitch ML, Craft S, Dowton SB, Ambrose P, Sparta S (1994) Interhemispheric transfer in children with early-treated phenylketonuria. J Clin Exp Neuropsychol 16:393–404
Güttler F, Lou H (1986) Dietary problems of phenylketonuria: effect on CNS transmitters and their possible role in behaviour and neuropsychological function. J Inherit Metab Dis 9:347–353
Hanley WB, Lee AW, Hanley AJ, Lehotay DC, Austin VJ, Schoonheyt WE, Platt BA, Clarke JT (2000) “Hypotyrosinemia” in phenylketonuria. Mol Genet Metab 69:286–294
Harmer CJ, McTavish SF, Clark L, Goodwin GM, Cowen PJ (2001) Tyrosine depletion attenuates dopamine function in healthy volunteers. Psychopharmacologia 154:105–111
Imamura T, Takanashi M, Hattori N, Fujimori M, Yamashita H, Ishii K, Yamadori A (1998) Bromocriptine treatment for perseveration in demented patients. Alzheimer Dis Assoc Disord 12:109–113
Kaufman S, Milstien S (1977) Phenylketonuria and its variants. Ann Clin Lab Sci 7:178–185
Kimberg DY, D’Esposito MD, Farah MJ (1997) Effects of bromocriptine on human subjects depend on working memory capacity. NeuroReport 8:3581–3583
Krause W, Halminski M, McDonald L, Dembure P, Salvo R, Freides D, Elsas L (1985) Biochemical and neuropsychological effects of elevated plasma phenylalanine in patients with treated phenylketonuria. J Clin Invest 75:40–48
Lezak M (1995) Neuropsychological assessment, 3rd edn. Oxford University Press, New York
Lou HC, Lykkelund C, Gerdes AM, Udesen H, Bruhn P (1987) Increased vigilance and dopamine synthesis by large doses of tyrosine or phenylalanine restriction in phenylketonuria. Acta Paediatr Scand 76:560–565
Luciana M, Collins PF (1997) Dopaminergic modulation of working memory for spatial but not object cues in normal humans. J Cognit Neurosci 9:330–347
Luciana M, Sullivan J, Nelson CA (2001) Individual differences in phenylalanine-to-tyrosine ratios moderate performance on tests of neuropsychological function in adolescents treated early and continuously for PKU. Child Dev 72:1637–1652
Lykkelund C, Nielsen JB, Lou HC, Rasmussen V, Gerdes AM, Christensen E, Guttler F (1988) Increased neurotransmitter biosynthesis in phenylketonuria induced by phenylalanine restriction or by supplementation of unrestricted diet with large amounts of tyrosine. Eur J Pediatr 148:238–245
Mazzoco MM, Nord AM, van Doorninck W, Greene CL, Kovar CG, Pennington BF (1994) Cognitive development among children with early-treated phenylketonuria. Dev Neuropsychol 10:133–151
McDowell S, Whyte J, D’Esposito MD (1998) Differential effect of a dopaminergic agonist on prefrontal function in traumatic brain injury patients. Brain 121:1155–1164
McKean CM, Petersen NA (1970) Glutamine in the phenylketonuric central nervous system. N Engl J Med 283:1364–1367
Mehta MA, Sahakian BJ, Robbins TW (2000) Comparative psychopharmacology of methylphenidate and related drugs in human volunteers, patients with attention-deficit hyperactivity disorder, and experimental animals. In: Solanto MV, Arnsten AFT, Castellanos FX (eds) Stimulant drugs and AD/HD: basic and clinical neuroscience. Oxford University Press, New York
Paans AM, Pruim J, Smit GP, Visser G, Willemsen AT, Ullrich K (1996) Neurotransmitter positron emission tomographic studies in adults with phenylketonura, a pilot study. Eur J Pediatr 155:878–881
Pelli DG, Robson JG, Wilkins AJ (1988) The design of a new letter chart for measuring contrast sensitivity. Clin Vis Sci 2:187–199
Pennington BF, van Doorninck WJ, McCabe LL, McCabe ER (1985) Neuropsychological deficits in early-treated phenylketonuric children. Am J Ment Defic 89:467–474
Pietz J, Kreis R, Schmidt H, Meyding-Lamade UK, Rupp A, Boesch C (1996) Phenylketonuria: fndings at MR imaging and localized in vivo H-1 MR spectroscopy of the brain in patients with early treatment. Radiology 201:413–420
Pietz J, Kreis R, Rupp A, Mayatepek E, Rating D, Boesch C, Bremer HJ (1999) Large neutral amino acids block phenylalanine transport into brain tissue in patients with phenylketonuria. J Clin Inves 103:1169–1178
Ris MD, Williams SE, Hunt MM, Berry HK, Leslie N (1994) Early-treated phenylketonuria: adult neuropsychologic outcome. J Pediatr 124:388–392
Sawaguchi T, Matsumura M, Kubota K (1988) Dopamine enhances the neuronal activity of a spatial short term memory task in the primate prefrontal cortex. Neurosci Res 5:465–473
Sawaguchi T, Matsumura,M, Kubota K (1990) Effects of dopamine antagonists on neuronal activity related to a delayed response task in monkey prefrontal cortex. J Neurophysiol 63:1401–1412
Ullrich K, Moller H, Weglage J, Schuierer G, Bick U, Ludolph A, Hahn-Ullrich H, Funders B (1994) White matter abnormalities in phenylketonuria: results of magnetic resonance measurements. Acta Paediatr Suppl 407:78–82
van Spronsen FJ, van Kijk T, Smit GP, van Rijn M, Reijngoud DJ, Berger R, Heymans HS (1996) Large daily fluctuations in plasma tyrosine in treated patients with phenylketonuria. Am J Clin Nutr 64:916–921
Vitiello B, Martin A, Hill J, Mack C, Molchan S, Martinez R, Murphy DL, Sunderland T (1997) Cognitive and behavioral effects of cholinergic, dopaminergic, and serotonergic blockade in humans. Neuropsychopharmacology 16:15–24
Wechsler D (1997) The Wechsler Adult Intelligence Scale, 3rd revision. The Psychological Corporation, San Antonio, Tex.
Weglage J, Pietsch M, Fünders B, Koch HG, Ullrich K (1996) Deficits in selective and sustained attention processes in early treated children with phenylketonuria—results of impaired frontal lobe functions? Eur J Pediatr 155:200–204
Welsh MC (1996) A prefrontal dysfunction model of early treated phenylketonuria. Eur J Pediatr 155:S87–89
Welsh MC, Pennington BF, Ozonoff S, Rouse B, McCabe ERB (1990) Neuropsychology of early-treated phenylketonuria: specific executive function deficits. Child Dev 61:1697–1713
White DA, Nortz MJ, Mandernach T, Huntington K, Steiner RD (2001) Deficits in memory strategy use related to prefrontal dysfunction during early development: evidence from children with phenylketonuria. Neuropsychology 13:221–229
White DA, Nortz MJ, Mandernach T, Huntington K, Steiner RD (2002) Age-related working memory impairments in children with prefrontal dysfunction associated with phenylketonuria. J Int Neuropsychol Soc 8:1–11
Williams GV, Goldman-Rakic PS (1995) Modulation of memory fields by dopamine D1 receptors in prefrontal cortex. Nature 376:572–575
Williams GV, Rao SG, Goldman-Rakic PS (2002) The physiological role of 5HT2A receptors in working memory. J Neurosci 22:2843–2854
Williamson ML, Koch R, Azen C, Chang C (1981) Correlates of intelligence tests results in treated phenylketonuric children. Pediatrics 68:161–167
Acknowledgements
This work was supported by a Grant-in-Aid of Research, Artistry, and Scholarship awarded to M.L. by the Office of the Vice President for Research at the University of Minnesota. The assistance of the General Clinical Research Center at the University of Minnesota, supported by grant M01-RR00400, from the National Center for Research Resources, the National Institute of Health is gratefully acknowledged. Blood assays for phenylalanine and tyrosine were conducted at Children’s National Medical Center in Washington, D.C. Thanks are extended to Mendel Tuchman for his support of this project. We would also like to thank Dorothy Markowitz for her assistance with the recruitment of PKU participants and the following individuals for their assistance with data collection: Taras Karkoc and Kristin Sullwold.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Luciana, M., Hanson, K.L. & Whitley, C.B. A preliminary report on dopamine system reactivity in PKU: acute effects of haloperidol on neuropsychological, physiological, and neuroendocrine functions. Psychopharmacology 175, 18–25 (2004). https://doi.org/10.1007/s00213-004-1775-0
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00213-004-1775-0